Sanofi and Translate Bio start clinical trial for mRNA flu vaccine

Flu seasons dominated by A/H3N2 strain circulation activity tend to be more severe

  
The logo of Sanofi is seen at the company's headquarters in Paris, France, April 24, 2020.

The logo of Sanofi is seen at the company's headquarters in Paris, France, April 24, 2020.

REUTERS/Charles Platiau

PARIS - French healthcare group Sanofi and U.S. partner Translate Bio have started a Phase I clinical trial evaluating an mRNA-based investigational vaccine against seasonal influenza, the companies said on Tuesday.

The trial will evaluate the safety and immunogenicity of a monovalent flu vaccine candidate coding for the hemagglutinin protein of the A/H3N2 strain of the influenza virus.

Flu seasons dominated by A/H3N2 strain circulation activity tend to be more severe, especially among those considered at risk, such as older adults and younger children, the companies added.

(Reporting by Sudip Kar-Gupta; Editing by Clarence Fernandez) ((sudip.kargupta@thomsonreuters.com; +33 1 49 49 53 84;))


More From Business